(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.81%.
Ovid Therapeutics's earnings in 2025 is -$26,433,000.On average, 4 Wall Street analysts forecast OVID's earnings for 2025 to be -$40,157,378, with the lowest OVID earnings forecast at -$45,488,003, and the highest OVID earnings forecast at -$35,537,503. On average, 4 Wall Street analysts forecast OVID's earnings for 2026 to be -$26,475,439, with the lowest OVID earnings forecast at -$52,595,504, and the highest OVID earnings forecast at $27,008,502.
In 2027, OVID is forecast to generate -$63,967,505 in earnings, with the lowest earnings forecast at -$63,967,505 and the highest earnings forecast at -$63,967,505.